
SNTI Stock Forecast & Price Target
SNTI Analyst Ratings
Bulls say
Senti Biosciences Inc. is poised for a positive outlook due to the successful performance of its product candidate SENTI-202, which has demonstrated statistically significant anti-tumor activity in preclinical models, indicating strong potential for efficacy in treating acute myeloid leukemia. The company's innovative use of allogeneic CAR-NK cells presents a favorable safety profile compared to traditional CAR-T therapies, positioning SENTI-202 strategically within a competitive landscape with limited offerings for similar therapies. Furthermore, the granting of orphan drug designation (ODD) suggests not only a promising regulatory pathway but also enhanced support from the FDA, which could facilitate expedited development and eventual market entry, reinforcing confidence in the company's clinical trajectory as it approaches critical data updates in late 2025.
Bears say
Senti Biosciences Inc faces several fundamental challenges contributing to a negative outlook on its stock. Key risks include potential safety concerns emerging from clinical programs, lower-than-expected efficacy results, and significant competition within the biotechnology sector, which could hinder the commercialization of its therapies. Additionally, the company requires substantial financing to maintain operations through 2040, raising concerns about its financial health and sustainability, especially given its current market capitalization of approximately $47 million, which is notably lower than its competitors in the allogeneic cell therapy space.
This aggregate rating is based on analysts' research of Senti Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
SNTI Analyst Forecast & Price Prediction
Start investing in SNTI
Order type
Buy in
Order amount
Est. shares
0 shares